Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

BUY
$4.35 - $6.17 $2,457 - $3,486
565 New
565 $2,000
Q4 2021

Feb 11, 2022

SELL
$7.67 - $44.59 $11,006 - $63,986
-1,435 Reduced 71.75%
565 $5,000
Q3 2021

Nov 10, 2021

BUY
$21.33 - $35.06 $42,660 - $70,120
2,000 New
2,000 $70,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $262M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track South State Corp Portfolio

Follow South State Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of South State Corp, based on Form 13F filings with the SEC.

News

Stay updated on South State Corp with notifications on news.